Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F21%3AA2202CTF" target="_blank" >RIV/61988987:17110/21:A2202CTF - isvavai.cz</a>

Alternative codes found

RIV/61988987:17110/21:A2202CTH RIV/00843989:_____/21:E0109014 RIV/65269705:_____/21:00075849

Result on the web

<a href="https://www.webofscience.com/wos/woscc/full-record/WOS:000691820800012?SID=D1v41LNKnqSuWlaZyU6" target="_blank" >https://www.webofscience.com/wos/woscc/full-record/WOS:000691820800012?SID=D1v41LNKnqSuWlaZyU6</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3324/haematol.2020.267831" target="_blank" >10.3324/haematol.2020.267831</a>

Result language

angličtina

Original language name

Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network

Original language description

For many decades, international collaborative efforts have driven therapeutic advances in multiple myeloma (MM). The establishment of uniform response criteria by the International Myeloma Working Group (IMWG) has been pivotal for this progress, as adherence to strict definitions ensures data comparability between trials. An essential prerequisite for the use of uniform criteria is the application of standardized methods. Of particular interest herein is the assessment of minimal residual disease (MRD) by multiparametric flow cytometry (MFC). This has been incorporated into the IMWG response criteria since 2011 to enable better risk stratification of a growing number of patients reaching a complete remission and has the promise to be used both as a surrogate marker for overall and progression-free survival and to inform treatment decisions.1,2 However, in contrast to most routine diagnostic tests for response assessment in MM, this assay has until recently suffered from large interlaboratory variations in terms of sample processing and data acquisition, resulting in highly heterogeneous sensitivities. 3 To enable uniform and sensitive MFC MRD assessment between laboratories, EuroFlow has developed standardized operating procedures.4-6 Their next-generation flow method has been incorporated as the gold standard for MFC MRD measurements in the latest IMWG response criteria, which is expected to greatly improve data validity and comparability.7

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

<a href="/en/project/NV17-30089A" target="_blank" >NV17-30089A: In-depth genomic analysis of residual clone in multiple myeloma: approach for individualized targeted therapy</a><br>

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2021

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Haematologica

ISSN

0390-6078

e-ISSN

—

Volume of the periodical

106

Issue of the periodical within the volume

5

Country of publishing house

IT - ITALY

Number of pages

4

Pages from-to

1496-1499

UT code for WoS article

000691820800012

EID of the result in the Scopus database

—